Integrated Biobank of Luxembourg, 6 rue Ernest Barble, L-1210 Luxembourg, Luxembourg.
Tuberculosis (Edinb). 2011 Nov;91(6):524-32. doi: 10.1016/j.tube.2011.07.006. Epub 2011 Aug 19.
Research for biomarkers supporting personalized medicine in infectious diseases is needed, especially for tuberculosis in which the existing toolbox does not yet address the public health priorities. Biobanks are essential infrastructures in this effort by collecting, authenticating and preserving human and/or bacterial specimens. A broad range of specimens should be collected prior to, during and following treatment, with a comprehensive characterisation of the sample donors and the samples themselves to accommodate the most recent technological platforms in biomarker research. This review explains current state-of-the-field biobanking practices in tuberculosis and suggests technical and managerial improvements to ensure long-term preservation and optimal use of the specimens. Open-access and certified biobanks are an essential component of a strategy supporting the development of drugs and diagnostic tests for both public health and personalised medicine. Biobanks have a role to play in the interaction between these two - not always compatible - approaches.
需要针对支持传染病个性化医学的生物标志物进行研究，尤其是在结核病方面，因为现有的工具包尚未解决公共卫生的优先事项。生物库是通过收集、验证和保存人类和/或细菌标本来进行这方面工作的重要基础设施。在治疗之前、期间和之后，应该收集广泛的标本，并对样本捐赠者和样本本身进行全面的描述，以适应生物标志物研究中最新的技术平台。这篇综述解释了结核病领域当前的生物库实践现状，并提出了技术和管理方面的改进建议，以确保标本的长期保存和最佳利用。开放获取和认证的生物库是支持开发用于公共卫生和个性化医学的药物和诊断测试的策略的重要组成部分。生物库在这两种（并不总是兼容）方法之间的相互作用中发挥作用。
